Pharma's Flu Drug Could Be Worth Billions, Analyst Says
Source: Brian Abrahams  (9/29/25)
Cidara Therapeutics Inc. (CDTX:NASDAQ) shares the minutes from an important meeting with the FDA, and the overall feedback was encouraging. Find out what one analyst predicts that will mean for Phase III development. More >

Biotech Discovers Breakthrough DMD Therapy Opportunity
Source: Dr. Leland Gershell  (9/26/25)
Capricor Therapeutics Inc. (CAPR:NASDAQ) recently announced a favorable regulatory update, according to a research note from Oppenheimer & Co Inc. More >

Healthcare Firm Targets Alzheimer's With Technology Breakthrough
Source: Streetwise Reports  (9/5/25)
Healthcare company Algernon Health (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) rebrands and unveils plan to open brain-specific PET scanning clinics in North America to meet rising demand for Alzheimer's diagnostics. Read more to learn how this shift positions the company at the center of a growing medical need. More >

Seeking Formulation of New Drug, Biopharma Co. Signs LOI
Source: Dr. Douglas Loe  (9/5/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report. More >

New Remission Data on MG Patients Compelling
Source: Mitchell Kapoor  (9/5/25)
Kyverna Therapeutics Inc.'s (KYTX:NASDAQ) KYV-101 cell therapy drives a 15-month and longer remission in three patients treated on a compassionate use basis, noted an H.C. Wainwright & Co. report. More >

Biopharma Firm Accelerates AI-Driven Cancer Drug Discovery in Canada
Source: Streetwise Reports  (9/3/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) secured fresh funding, advanced preclinical PARP and ATR programs, and leveraged exclusive AI platforms to target DNA-repair pathways. Read more for insight into its expanding role in precision oncology. More >

Cell Therapy Firm Kyverna Advances U.S. Phase 3 MG Trial
Source: Streetwise Reports  (9/3/25)
Kyverna Therapeutics Inc. (KYTX:NASDAQ) unveiled the design of its U.S. registrational Phase 3 trial for KYV-101 in myasthenia gravis during a Key Opinion Leader event, following ≥ 15-month remission data in Germany. Read more to see what sets this trial apart. More >

Healthcare AI Company Rebrands as Rocket Doctor AI to Pursue Growing Market Opportunities
Source: Streetwise Reports  (8/27/25)
Treatment.com AI Inc. has rebranded and reincorporated as Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) to reflect the integration of its proprietary AI-driven Global Library of Medicine (GLM) with the recently acquired Rocket Doctor Inc. Read why one analyst calls part of the company's offerings "Shopify for physicians." More >

AI Healthcare Stock Showing Signs of a Base Breakout
Source: John Newell  (8/25/25)
John Newell of John Newell & Associates explains why he thinks Rocket Doctor AI (AIDR:CSE; TREIF:OTC; 939:FRA) is a Speculative Buy. More >

Cleantech Co. Advances Innovative Systems for Data Centers
Source: Streetwise Reports  (8/19/25)
Environmental and cleantech company BioLargo Inc. (BLGO:OTCQX) announces its financial results, including a huge increase in revenue in its engineering segment due to contracts to provide control compliance services. More >

Co.'s Graphene Used in New Screening Test for Lung Cancer
Source: Streetwise Reports  (8/18/25)
HydroGraph Clean Power Inc.'s (HG:CSE; HGRAF:OTCQB; M98:FSE) patented, high-purity material has applications in healthcare, as in this case, but also in numerous other industries. Read on to learn why some experts say this company could be a future 100-bagger. More >

AI Biotech Company Plans Saudi Venture to Develop Cancer Drug
Source: Streetwise Reports  (8/14/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) has signed a Letter of Intent with NanoPalm to co-develop AI-discovered cancer treatments starting with kt-3283. Read how the experimental drug targets hard-to-treat tumors and may signal a broader pipeline to come More >

Medical Co.'s New Joint Venture Could Expand Co.'s Footprint
Source: Dr. Douglas Loe  (8/13/25)
Leede Financial Inc. analyst Dr. Douglas Loe gave this company a Buy rating. More >

Pharmaceutical Company Discovers Breakthrough Heart Treatment in Canada
Source: Jason Wittes  (8/11/25)
Top-line results from Cardiol Therapeutics' (CRDL:TSX; CRDL:NASDAQ) ARCHER study for Acute Myocarditis are quite promising, writes Roth Capital Partners Analyst Jason Wittes in an updated research note. More >

Biotech Announces Topline Results From Cardiovascular Drug Trial
Source: Brandon Folkes  (8/11/25)
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) Analyst Brandon Folkes reviews Cardiol Therapeutics Inc. after it announced the topline results from its Phase II ARCHER trial of CardiolRx in acute myocarditis. More >

Canadian Pharmaceutical Company Discovers Breakthrough Cardiovascular Treatment
Source: Streetwise Reports  (8/11/25)
Clinical-stage life sciences company Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) announces topline results from its Phase II clinical study involving patients with acute myocarditis. Read why analysts like this pharmaceutical stock. More >

Canadian Pharma Finds Promising Cardiovascular Breakthrough
Source: Douglas Loe  (8/8/25)
Cardiol Therapeutics (CRDL:TSX; CRDL:NASDAQ) reports headline Phase II data from its 109-patient acute myocarditis study, known as the ARCHER trial. Read to see how one analyst rates the stock. More >

Cleantech/Life Sciences Co. Advances Products in Q2/25
Source: Richard Ryan  (8/4/25)
BioLargo Inc. (BLGO:OTCQX) enters into several agreements, forms partnerships and receives third party product validation, noted an Oak Ridge Financial report. More >

Clean Tech Firm Making Important PFAS Breakthrough
Source: Streetwise Reports  (7/29/25)
Clean technology company BioLargo Inc. (BLGO:OTCQX) president and chief executive office shares a mid-year update on the company's achievements so far this year, along with insights into its future prospects through a letter to shareholders. More >

Cancer Drug Developer Finds Potent Hits With AI in British Columbia
Source: Streetwise Reports  (7/25/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) taps machine learning to zero in on novel cancer therapies. Read more about the AI engine driving this high-stakes discovery. More >

Pancreas Cancer Becoming Top Focus for Biotech Co.?
  (7/22/25)
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) published survival data for the use of its immunotherapy pelareorep in pancreatic cancer, and these support the view that this indication should be primary, noted a Leede Financial Inc. report. More >

Biotech Firm Clears Major U.S. Trading Hurdle
Source: Streetwise Reports  (7/18/25)
Rakovina Therapeutics Inc. (RKV:TSX.V) just gained DTC eligibility, opening the door for faster U.S. trades and broader investor access. With AI-driven cancer drugs in development, analysts are taking notice. Read more to find out why. More >

Portable Rapid Testing Kit Drives Development of 'Forever Chemical' Solution
Source: Streetwise Reports  (7/15/25)
BioLargo Inc. (BLGO:OTCQX) announced it has initiated "alpha testing" of a PFAS-detecting portable water test kit. Find out why one analyst says the stock is a Buy. More >

Biotech Partnership to Revolutionize Diabetes Treatment
Source: Streetwise Reports  (7/15/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces a collaborative research agreement with Eledon Pharmaceuticals Inc. to assess Eledon's immunosuppressive drug in Sernova's ongoing trials of its cell pouch biohybrid organ for patients with Type 1 diabetes (T1D). More >

Biotech Enters Agreement with Co. Behind Tegoprubart
Source: Dr. Joseph Pantginis  (7/14/25)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) likely will use this new monoclonal antibody as an immunosuppressant in its Phase 1/2 trial's Cohort C instead of previously used tacrolimus, noted an H.C. Wainwright & Co. report. More >